Frontline treatment for epilepsy is based on small molecule drugs that target ion channels and neurotransmitter systems, including levetiracetam and other synaptic vesicle glycoprotein 2A (SV2A)-modulating compounds (Kwan et al., 2011; Loscher et al., 2016). This evidence concerns the gene SV2A and epilepsy.